Pharmacotherapy for treatment-refractory schizophrenia

Scott Van Sant, Peter F Buckley

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a large percentage of persons with schizophrenia remain at least partially nonresponsive to treatment, leading to increased morbidity/mortality, increased healthcare cost, and poor quality of life for affected individuals. Areas covered: This paper comprises a review of recent research in drug therapy for schizophrenia, particularly treatment-refractory schizophrenia, with a focus on research conducted between 2005 and June 2010. Databases that were searched include: Pubmed, CINAHL, Science Direct, Medline and Clinical Trials.gov. Primary search terms were 'treatment-refractory schizophrenia' and 'treatment-resistant schizophrenia', with cross reference to specific agents covered in this article. An objective perspective on current trends in pharmacotherapy for treatment-refractory schizophrenia. We review the available evidence and discuss the strengths and weaknesses of published data in this field. Expert opinion: Although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice.

Original languageEnglish (US)
Pages (from-to)411-434
Number of pages24
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Schizophrenia
Drug Therapy
Therapeutics
Expert Testimony
Research
PubMed
Health Care Costs
Quality of Life
Clinical Trials
Databases
Morbidity
Safety
Mortality

Keywords

  • pharmacotherapy
  • refractory
  • schizophrenia
  • treatment-resistant

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy for treatment-refractory schizophrenia. / Van Sant, Scott; Buckley, Peter F.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 3, 01.02.2011, p. 411-434.

Research output: Contribution to journalReview article

Van Sant, Scott ; Buckley, Peter F. / Pharmacotherapy for treatment-refractory schizophrenia. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 3. pp. 411-434.
@article{976e01f497404e25b8bdbfdcb9429016,
title = "Pharmacotherapy for treatment-refractory schizophrenia",
abstract = "Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a large percentage of persons with schizophrenia remain at least partially nonresponsive to treatment, leading to increased morbidity/mortality, increased healthcare cost, and poor quality of life for affected individuals. Areas covered: This paper comprises a review of recent research in drug therapy for schizophrenia, particularly treatment-refractory schizophrenia, with a focus on research conducted between 2005 and June 2010. Databases that were searched include: Pubmed, CINAHL, Science Direct, Medline and Clinical Trials.gov. Primary search terms were 'treatment-refractory schizophrenia' and 'treatment-resistant schizophrenia', with cross reference to specific agents covered in this article. An objective perspective on current trends in pharmacotherapy for treatment-refractory schizophrenia. We review the available evidence and discuss the strengths and weaknesses of published data in this field. Expert opinion: Although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice.",
keywords = "pharmacotherapy, refractory, schizophrenia, treatment-resistant",
author = "{Van Sant}, Scott and Buckley, {Peter F}",
year = "2011",
month = "2",
day = "1",
doi = "10.1517/14656566.2011.528200",
language = "English (US)",
volume = "12",
pages = "411--434",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacotherapy for treatment-refractory schizophrenia

AU - Van Sant, Scott

AU - Buckley, Peter F

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a large percentage of persons with schizophrenia remain at least partially nonresponsive to treatment, leading to increased morbidity/mortality, increased healthcare cost, and poor quality of life for affected individuals. Areas covered: This paper comprises a review of recent research in drug therapy for schizophrenia, particularly treatment-refractory schizophrenia, with a focus on research conducted between 2005 and June 2010. Databases that were searched include: Pubmed, CINAHL, Science Direct, Medline and Clinical Trials.gov. Primary search terms were 'treatment-refractory schizophrenia' and 'treatment-resistant schizophrenia', with cross reference to specific agents covered in this article. An objective perspective on current trends in pharmacotherapy for treatment-refractory schizophrenia. We review the available evidence and discuss the strengths and weaknesses of published data in this field. Expert opinion: Although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice.

AB - Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a large percentage of persons with schizophrenia remain at least partially nonresponsive to treatment, leading to increased morbidity/mortality, increased healthcare cost, and poor quality of life for affected individuals. Areas covered: This paper comprises a review of recent research in drug therapy for schizophrenia, particularly treatment-refractory schizophrenia, with a focus on research conducted between 2005 and June 2010. Databases that were searched include: Pubmed, CINAHL, Science Direct, Medline and Clinical Trials.gov. Primary search terms were 'treatment-refractory schizophrenia' and 'treatment-resistant schizophrenia', with cross reference to specific agents covered in this article. An objective perspective on current trends in pharmacotherapy for treatment-refractory schizophrenia. We review the available evidence and discuss the strengths and weaknesses of published data in this field. Expert opinion: Although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice.

KW - pharmacotherapy

KW - refractory

KW - schizophrenia

KW - treatment-resistant

UR - http://www.scopus.com/inward/record.url?scp=79251469125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251469125&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.528200

DO - 10.1517/14656566.2011.528200

M3 - Review article

C2 - 21254948

AN - SCOPUS:79251469125

VL - 12

SP - 411

EP - 434

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 3

ER -